In a setback for Novo Nordisk, a U.S. judge dismissed its lawsuit accusing a compound pharmacy of selling versions of its Wegovy and Ozempic medicines, which are widely prescribed for weight loss and have become franchise products for the drug company.
The decision, which was conveyed in a one-page filing in the court docket, comes after Novo Nordisk filed lawsuits last July against Brooksville Pharmaceuticals and three other compound pharmacies for allegedly violating laws in different states. The drug maker argued the compounders were selling versions of its medicines that were never approved by the U.S. Food and Drug Administration.
The compound pharmacy declined to comment, as did its attorney, Matthew Modafferi. However, he explained that U.S. District Court Judge William Jung left the door open for Novo Nordisk to file an amended lawsuit. This suggests the case may continue if drug maker takes such a step. A Novo Nordisk spokeswoman told us the company plans to file an amended lawsuit explaining why it believes the pharmacy violated Florida state law.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.